stockrow
Saturday 7 November 2026
Export WVE’s income statement to Excel — free account
WAVE Life Sciences Ltd.
WAVE Life Sciences Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $42.7 million, down 60.5% from fiscal 2024.
- Revenue
- +73.0%
- EPS
- +5.25%
- Free cash flow
- −33.9%
Quarter to September 2026, against a year earlier
3.36
0.14
+4.35%
Follow WVE
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (79.98%) | (68.31%) | (53.72%) | (56.16%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
3 | 4 | 3 | 3 | |
| (56.19%) | (49.95%) | (42.11%) | (41.26%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(51.34%) | (43.68%) | (35.41%) | (38.77%) | |
Average Days of Receivables |
61.76 | 4.96 | 0.00 | 10.90 | |
Free Cash Flow per Share |
(1.02) | (0.95) | (0.92) | (1.12) | |
Free Cash Flow |
(208.39) | (193.15) | (185.00) | (188.21) | |
Capital Expenditures |
(1.34) | (1.57) | (0.99) | (0.72) | |
| Other line items | |||||
Cash ROIC |
(25.03%) | (20.46%) | (17.51%) | (16.80%) | |
Accounts Receivable Turnover |
10.42 | 56.60 | 0.00 | 33.30 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
289.60% | 302.00% | 264.07% | 427.78% | |
Selling, General and Administrative Expense of Revenue |
131.34% | 131.36% | 110.14% | 176.31% | |
Share Based Compensation of Revenue |
52.79% | 51.43% | 40.51% | 58.45% | |
Operating CF/Net income |
0.98 | 0.95 | 1.00 | 0.92 | |
Depreciation/Fixed assets |
1.48 | 1.34 | 1.27 | 1.20 | |
Capex/Depreciation |
(0.14) | (0.17) | (0.11) | (0.08) | |
Revenue per Share |
0.35 | 0.32 | 0.36 | 0.25 | |
Operating CF per Share |
(1.01) | (0.94) | (0.92) | (1.11) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.01 | 0.02 |
Columns are period end dates · fundamentals updated 2 Nov 2026